Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?

Purpose: The long-term biochemical relapse-free survival and overall survival were compared for patients receiving either radiotherapy (RT) alone or radiotherapy combined with a short-course of total androgen suppression for failure after radical prostatectomy. Methods and Materials: Between 1985 and 2001, a total of 122 patients received RT after radical prostatectomy at our institution. Fifty-three of these patients received a short-course of total androgen suppression (TAS) 2 months before and 2 months concurrent with RT with a nonsteroidal antiandrogen and an luteinizing hormone-releasing hormone (LHRH) agonist (combined therapy group); the remaining 69 patients received RT alone. Treatment failure was defined after postoperative RT as a detectable PSA>0.05 ng/mL. Clinical and treatment variables examined included: presurgical PSA, clinical T stage, pathologic Gleason sum (pGS), seminal vesicle (SV) involvement, lymph node involvement, surgical margins, pre-RT PSA, prostate dose, pelvic irradiation, indication for postoperative RT (salvage or adjuvant), and time interval between surgery and RT. Minimum follow-up after postoperative RT was 1 year and median follow-up was 5.9 years (maximum, 14 years) for patients receiving RT alone, and 3.9 years (maximum, 11 years) for patients receiving RT with TAS (combined therapy group). Kaplan-Meier analysis was performed for PSA failure-free survival (bNED) and for overall survival (OS). Cox proportional hazards multivariable analysis examined the influence all clinical and treatment variables predicting for bNED and OS. Results: The median time to PSA failure after postoperative RT was 1.34 years for the combined therapy group and 0.97 years for the RT alone group (p=0.19), with no failures beyond 5 years. At 5 years, the actuarial bNED rates were 57% for the combined therapy group compared with 31% for the RT alone group (P=0.0012). Overall survival rates at 5 years were 100% for the combined therapy group compared with 87% for the RT alone group (p=0.0008). For pGS less than or equal to7, the 5-year bNED rates were 58% for combined therapy and 38% for RT alone (p=0.0155), and for pGS greater than or equal to8 the 5-year bNED rates were 65% for combined therapy and 17% for RT alone (p=0.075). The 5-year OS rates for pGS less than or equal to7 were 100% for combined therapy and 98% for RT alone group (p=0.106), and the 5-year OS for pGS greater than or equal to8 was 100% for combined therapy and 54% for RT alone (p=0.04). On multivariable analysis, only SV involvement (p=0.0145) and the addition of short-course TAS to postoperative RT (p=0.0019) were significant covariates predicting for bNED and, similarly, approached significance for overall survival (p=0.0594 and p=0.0856, respectively). Conclusions: Radiotherapy combined with a short-course TAS after radical prostatectomy appears to confer a PSA relapse-free survival advantage and possibly an overall survival advantage when compared with RT alone. The hypothesis that a transient course of androgen suppression with salvage or adjuvant RT after prostatectomy improves outcomes will need to be tested in a randomized trial. (C) 2004 Elsevier Inc.